Showing results (251-260 of 267) with videos related to

Sort By:
Pageof 27
The Australian and New Zealand Journal of Psychiatry|May 20, 1998
The relationship between fatigue, psychological and immunological variables in acute infectious illnessB K Bennett, I B Hickie, U S Vollmer-Conna, et al.
Bioorganic & Medicinal Chemistry Letters|October 28, 2008
Bacterial translation inhibitors, 1-acylindazol-3-ols as anthranilic acid mimicsCory Stiff, David R Graber, Atli Thorarensen, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 24, 2012
Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipationRobert W Busby, Marco M Kessler, Wilmin P Bartolini, et al.
The Journal of Pediatrics|April 25, 2007
Validity, reliability, and responsiveness of a new measure of health-related quality of life in children with immune thrombocytopenic purpura: the Kids' ITP ToolsRobert J Klaassen, Victor S Blanchette, Dorothy Barnard, et al.
Pharmacology Research & Perspectives|April 22, 2020
Pharmacokinetics, mass balance, tissue distribution, metabolism, and excretion of praliciguat, a clinical-stage soluble guanylate cyclase stimulator in ratsAli R Banijamali, Andrew E Carvalho, James D Wakefield, et al.
The Australian and New Zealand Journal of Psychiatry|September 5, 2001
What is chronic fatigue syndrome? Heterogeneity within an international multicentre studyA Wilson, I Hickie, D Hadzi-Pavlovic, et al.
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]|January 23, 2008
An inhibitor of methionine aminopeptidase type-2, PPI-2458, ameliorates the pathophysiological disease processes of rheumatoid arthritisD D Lazarus, E G Doyle, S G Bernier, et al.
Clinical Journal of the American Society of Nephrology : CJASN|December 17, 2020
Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical TrialJohn P Hanrahan, Ian H de Boer, George L Bakris, et al.
EJNMMI Research|February 16, 2024
Synthesis and preclinical evaluation of [11C]EAI045 as a PET tracer for imaging tumors expressing mutated epidermal growth factor receptorAntonia A Högnäsbacka, Alex J Poot, Christophe Plisson, et al.
Diabetologia|December 21, 2019
An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertensionJohn P Hanrahan, Jelena P Seferovic, James D Wakefield, et al.
Pageof 27